Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
September 20, 2017
Juno Therapeutics (JUNO) proposes $225 M follow-on offering
August 31, 2017
VistaGen (VTGN) prices 1.37 M share offering at $1.75 with 1.89 M warrants attached
June 27, 2017
Histogenics (HSGX) P3 Clinical Trial of Neocart® enrollment completed to Treat Knee Cartilage Damage - BUY
June 26, 2017
bluebird bio (BLUE) prices $350 M share offering at $105.00
June 20, 2017
Sangamo Therapeutics (SGMO) proposes $72.5 M offering
June 12, 2017
Fibrocell Science (FCSC) gets “Rare Pediatric Disease Designation” from FDA
June 1, 2017
Biostage (BSTG) disclosure of material information re a wrongful death complaint
May 31, 2017
Cytori (CYTX) executes $13.4 M Option for burn clinical trial with BARDA
May 12, 2017
Capricor (CAPR) bites the bullet that they fired at itself
May 3, 2017
Randy Mills' Departs the California Institute for Regenerative Medicine (CIRM) in June
April 10, 2017
Cytori (CYTX) 8.6 M share offering priced at $1.10 after stock jumps on BARDA news
April 4, 2017
Mesoblast Limited (ASX: MSB) (MESO) on news of the FDA clearing trial for hypoplastic left heart syndrome (HLHS)
April 1, 2017
Capricor Therapeutics (CAPR) at-the-market offering of $5 M
March 27, 2017
RegMed Investors’ (RMi) mid-day analysis, retracing
March 27, 2017
Mesoblast (MESO) $40 M offering of 26.25 M shares priced at AUS2.00
March 22, 2017
Bellicum Pharmaceuticals (BLCM) proposes 5M share offering at $12.00 per share
March 21, 2017
REGENXBIO (RGNX) proposes 3.7 M share offering priced at $20.50 for proceeds of $75 M
March 17, 2017
Northwest Bio (NWBO) yet another offering, this time of $7.5 M
March 13, 2017
Fate Therapeutics (FATE) FDA clears an IND for FATE-NK100
March 10, 2017
Fibrocell (FCSC) 1 for 3 reverse stock split
March 9, 2017
Histogenics (HSGX) publication of peer reviewed in the Journal of Orthopaedic Research
March 7, 2017
Fibrocell Sciences (FCSC) proposes convertible preferred 8 M unit financing for $8 M
March 2, 2017
Kite Pharma (KITE) proposes 4.75 M share offering priced at $75.00
7 hours 49 min ago
RegMed Investors’ (RMi) pre-open: What’s next …
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.